Aethlon Medical to Release Fiscal Second Quarter Financial Results and Host Conference Call on November 13, 2024
Aethlon Medical (Nasdaq: AEMD), a medical therapeutic company developing products for cancer and infectious diseases treatment, announced it will release its fiscal second quarter financial results for the period ended September 30, 2024, on November 13, 2024 at 4:15 p.m. ET. The company will host a conference call at 4:30 p.m. ET the same day, featuring management's remarks and a Q&A session. Participants can register online or dial in directly, with replay available until December 13, 2024.
Aethlon Medical (Nasdaq: AEMD), un'azienda terapeutica medica che sviluppa prodotti per il trattamento del cancro e delle malattie infettive, ha annunciato che rilascerà i suoi risultati finanziari del secondo trimestre fiscale per il periodo conclusosi il 30 settembre 2024, il 13 novembre 2024 alle 16:15 ET. L'azienda ospiterà una conferenza telefonica alle 16:30 ET lo stesso giorno, con interventi della direzione e una sessione di domande e risposte. I partecipanti possono registrarsi online o chiamare direttamente, con una registrazione disponibile fino al 13 dicembre 2024.
Aethlon Medical (Nasdaq: AEMD), una empresa terapéutica médica que desarrolla productos para el tratamiento del cáncer y enfermedades infecciosas, anunció que publicará sus resultados financieros del segundo trimestre fiscal para el período terminado el 30 de septiembre de 2024, el 13 de noviembre de 2024 a las 4:15 p.m. ET. La empresa realizará una conferencia telefónica a las 4:30 p.m. ET el mismo día, con comentarios de la dirección y una sesión de preguntas y respuestas. Los participantes pueden registrarse en línea o llamar directamente, con una repetición disponible hasta el 13 de diciembre de 2024.
Aethlon Medical (Nasdaq: AEMD), 암 및 감염병 치료를 위한 제품을 개발하는 의료 치료 회사가 2024년 9월 30일 종료된 기간에 대한 회계 연도 두 번째 분기 재무 결과를 2024년 11월 13일 오후 4시 15분 ET에 발표할 것이라고 발표했습니다. 회사는 같은 날 오후 4시 30분 ET에 경영진의 발언과 질의응답 세션을 포함한 전화 회의를 개최할 예정입니다. 참가자는 온라인으로 등록하거나 직접 전화로 참여할 수 있으며, 재생 기능은 2024년 12월 13일까지 제공됩니다.
Aethlon Medical (Nasdaq: AEMD), une entreprise de thérapie médicale développant des produits pour le traitement du cancer et des maladies infectieuses, a annoncé qu'elle publiera ses résultats financiers du deuxième trimestre fiscal pour la période se terminant le 30 septembre 2024, le 13 novembre 2024 à 16h15 ET. L'entreprise organisera une conférence téléphonique le même jour à 16h30 ET, avec des remarques de la direction et une session de questions-réponses. Les participants peuvent s'inscrire en ligne ou composer le numéro directement, avec une rediffusion disponible jusqu'au 13 décembre 2024.
Aethlon Medical (Nasdaq: AEMD), ein medizinisches Therapeutikunternehmen, das Produkte zur Behandlung von Krebs und Infektionskrankheiten entwickelt, hat angekündigt, dass es seine Finanzergebnisse des zweiten Geschäftsquartals für den Zeitraum bis zum 30. September 2024 am 13. November 2024 um 16:15 Uhr ET veröffentlichen wird. Das Unternehmen wird am selben Tag um 16:30 Uhr ET eine Telefonkonferenz abhalten, die die Anmerkungen des Managements und eine Fragerunde umfasst. Teilnehmer können sich online registrieren oder direkt einwählen, und die Aufzeichnung ist bis zum 13. Dezember 2024 verfügbar.
- None.
- None.
Management will host a conference call on Wednesday, November 13, 2024, at 4:30 p.m. ET to review financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session.
Interested parties can register for the conference call by navigating to https://dpregister.com/sreg/10194285/fdebe88214. Please note that registered participants will receive their dial-in number upon registration.
Interested parties without internet access or unable to pre-register may dial in by calling:
PARTICIPANT DIAL IN (TOLL FREE): 1-844-836-8741
PARTICIPANT INTERNATIONAL DIAL IN: 1-412-317-5442
All callers should ask for the Aethlon Medical, Inc. conference call.
A replay of the call will be available approximately one hour after the end of the call through December 13, 2024. The replay can be accessed via Aethlon Medical's website or by dialing 1-877-344-7529 (domestic) or 1-412-317-0088 (international) or
About Aethlon and the Hemopurifier®
Aethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and in pre-clinical studies, the Hemopurifier has demonstrated the removal of harmful exosomes from biological fluids, utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a
Additional information can be found at www.AethlonMedical.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Aethlon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.
Company Contact:
Jim Frakes
Chief Executive Officer and Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.com
Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com
View original content:https://www.prnewswire.com/news-releases/aethlon-medical-to-release-fiscal-second-quarter-financial-results-and-host-conference-call-on-november-13-2024-302297316.html
SOURCE Aethlon Medical, Inc.
FAQ
When will Aethlon Medical (AEMD) release its Q2 2024 financial results?
How can investors join Aethlon Medical's (AEMD) Q2 2024 earnings call?